HC Wainwright Reaffirms Buy Rating for Tetraphase Pharmaceuticals (TTPH)

Tetraphase Pharmaceuticals (NASDAQ:TTPH)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a research report issued on Tuesday. They currently have a $17.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price target indicates a potential upside of 212.50% from the company’s current price.

The analysts wrote, “a Highly Favorable Risk/Reward; Affirm Buy Stock Data 02/05/2018 Price $5.19 Exchange NASDAQ Price Target $17.00 52-Week High $9.93 52-Week Low $4.04 Enterprise Value (M) $106.6 Market Cap (M) $268 Public Market Float (M) 37.5 Shares Outstanding (M) 51.6 3 Month Avg Volume 477,304 Short Interest (M) 2.97 Shares Outstanding (M): Figure shown is as of January 24, 2018. Balance Sheet Metrics Cash (M) $161.4 Total Debt (M) $0.0 Total Cash/Share $3.13 Book Value/Share $2.78 Cash (M): Figure shown is as of September 30, 2017. EPS Diluted Full Year – Dec 2016A 2017E 2018E 1Q (0.46) (0.79)A (0.56) 2Q (0.47) (0.83)A (0.55) 3Q (0.58) (0.63)A (0.54) 4Q (0.61) (0.60) (0.52) FY (2.11) (2.80) (2.17) Revenue ($M) Full Year – Dec 2016A 2017E 2018E 1Q 2.0 1.5A 1.5 2Q 1.2 1.6A 1.0 3Q 0.9 4.1A 1.2 4Q 1.1 2.0 1.5 FY 5.1 9.1 5.2 10 8 6 4 2 FEB- 17 J UN- 17 OCT- 17 FEB- 18 20 15 10 5 0 Vol. (mil) Price cUTI: We believe IGNITE3 will be a solid, clean win.””

Several other equities analysts have also recently commented on the stock. BidaskClub cut shares of Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday. Zacks Investment Research raised shares of Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, January 12th. Finally, ValuEngine cut shares of Tetraphase Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $15.15.

Tetraphase Pharmaceuticals (NASDAQ TTPH) traded up $0.25 during trading on Tuesday, reaching $5.44. 462,670 shares of the company’s stock traded hands, compared to its average volume of 418,437. The firm has a market cap of $279.70, a PE ratio of -1.90 and a beta of 2.28. Tetraphase Pharmaceuticals has a 52-week low of $4.04 and a 52-week high of $9.93.

In other news, insider Jacques Dumas sold 8,750 shares of Tetraphase Pharmaceuticals stock in a transaction that occurred on Tuesday, January 30th. The shares were sold at an average price of $6.22, for a total value of $54,425.00. Following the transaction, the insider now owns 8,750 shares of the company’s stock, valued at approximately $54,425. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director L Patrick Gage acquired 3,880 shares of the stock in a transaction dated Wednesday, November 29th. The stock was acquired at an average cost of $6.45 per share, for a total transaction of $25,026.00. Following the purchase, the director now directly owns 38,880 shares in the company, valued at $250,776. The disclosure for this purchase can be found here. Insiders own 5.50% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in TTPH. Schwab Charles Investment Management Inc. grew its stake in shares of Tetraphase Pharmaceuticals by 0.7% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 129,681 shares of the biopharmaceutical company’s stock worth $925,000 after purchasing an additional 874 shares during the last quarter. Bank of New York Mellon Corp grew its stake in shares of Tetraphase Pharmaceuticals by 3.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 194,144 shares of the biopharmaceutical company’s stock worth $1,384,000 after purchasing an additional 6,247 shares during the last quarter. Alliancebernstein L.P. grew its stake in shares of Tetraphase Pharmaceuticals by 6.9% in the 2nd quarter. Alliancebernstein L.P. now owns 59,200 shares of the biopharmaceutical company’s stock worth $422,000 after purchasing an additional 3,800 shares during the last quarter. Ameriprise Financial Inc. acquired a new position in shares of Tetraphase Pharmaceuticals in the 2nd quarter worth approximately $162,000. Finally, GSA Capital Partners LLP acquired a new position in shares of Tetraphase Pharmaceuticals in the 2nd quarter worth approximately $205,000. 58.36% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “HC Wainwright Reaffirms Buy Rating for Tetraphase Pharmaceuticals (TTPH)” was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another site, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The legal version of this article can be read at https://www.americanbankingnews.com/2018/02/06/hc-wainwright-reaffirms-buy-rating-for-tetraphase-pharmaceuticals-ttph.html.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Analyst Recommendations for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply